Inhibitor development in prospective clinical trials with recombinant factor VIII preparations in previously untreated patients.
Lusher
J M
JM
Children's Hospital of Michigan, Department of Pediatrics, Detroit, Mich., USA.
D002986:Clinical Trials as Topic; D005169:Factor VIII / Q000276:immunology / Q000627:therapeutic use*; D006467:Hemophilia A / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects; D007518:Isoantibodies / Q000009:adverse effects / Q000097:blood / Q000187:drug effects; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000276:immunology / Q000627:therapeutic use
D007518:Isoantibodies; D011994:Recombinant Proteins; C078147:F8 protein, human; D005169:Factor VIII